BPIPO and DCB Partner with LINK-J for the First Regenerative Medicine Investment Event in Tokyo

TOKYO,April 29, 2025/PRNewswire/ -- The inaugural Taiwan-Japan Investment and Industry Networking Event took place at the Global Life Science Hub inTokyo. The forum united leading biotech and pharmaceutical companies to explore cross-border investment, technology collaboration, and market growth. Key organizations—including BPIPO, DCB, LINK-J, and FIRM—highlighted partnership in regenerative medicine and drug innovation, aiming to bridgeTaiwan'sbiotech strengths withJapan'sinvestment and clinical development capabilities.

7 Taiwanese Companies Showcase Regenerative Medicine, Immuno-Oncology, and Precision Healthcare

Mr.Keita Komatsu, Deputy Director of the Bio-Industry Division atJapan'sMinistry of Economy, Trade and Industry (METI), expressed optimism for increased support in regenerative medicine investment programs betweenTaiwanandJapan. During the event, 6 leading Japanese venture capital firms and 30 pharmaceutical and biotech companies, including DCI Partners and Eight Roads Ventures, offered insights and emerging technologies.

Seven Taiwanese regenerative medicine companies were selected to showcase at the event, including:

DuoGenic StemCells Corporation highlighted its stem cell therapies for degenerative diseases. ChairmanHong-Lin Sunoted,"Our 3-in-1 solution—platelet-rich fibrin, PBMCs, and growth factors—combines physical and chemical components to control osteoarthritis."In a similar vein,Ascension Medical Biotechnology Co., Ltd.emphasized its integrated GMP manufacturing and clinical trial results."We can induce over 100 types of exosomes, targeting a range of diseases,"Chairman DrRichard Shiehexplained.

For cancer care,AngenMed Therapeutics, Inc.presented its immuno-oncology therapies for solid tumors. CEO Shuen-iu Hung stated,"We enable precise anti-tumor immunity and long-term surveillance. Integrating clinical services and trials inJapanwill accelerate our impact."

Meanwhile,GNT Inc.showcased its nanotech and dermatology. ChairmanShan-Wen Tangsaid"GNT.Tec6, a needle-free, supersonic device for painless, non-invasive drug delivery also deliver exosomes hair follicle, promoting hair growth."

Similarly,HeXun Biosciences Co., Ltd.offers full CDMO services from R&D to GMP production using automated systems. Vice GMSung Yuan Chensaid,"Automation boosts consistency and helps clients speed up development and ensure quality.

Furthermore,BIONET Therapeutics Corp.presented its AI-driven approach to cell therapies and exosome development."AI streamlines data analysis and treatment optimization,"said Special AssistantFiona Tsai."We're ready to take our exosome platform global."

Finally,LumiSTAR Biotechnology, Inc.featured its iPSC Regenerative Medicine& Drug Screening Platform. Senior BD ManagerChih-Chuan Suremarked,"The tech may be complex, but the goal—faster drug discovery—is simple."

Collectively, these companies highlightTaiwan'svibrant biotech ecosystem, advancing global healthcare through regenerative medicine, oncology, diagnostics, and AI innovation.

DuoGenic StemCells and A&I Corporation Enter Licensing Agreement

A key highlight was the signing of a licensing agreement betweenTaiwan-based DuoGenic StemCells andJapan'sA&I Corporation, facilitated by BPIPO and FIRM. The deal grants A&I rights to DuoGenics'AI Cells technology, therapeutic approvals, marketing, and sales inJapan, marking a milestone inTaiwan-Japanbiotech collaboration.

The event not only opens new opportunities for biotech companies but also advances a robust biotech ecosystem rooted in cross-border collaboration.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/bpipo-and-dcb-partner-with-link-j-for-the-first-regenerative-medicine-investment-event-in-tokyo-302441068.html

SOURCE BPIPO